Muñoz-Garza FZ, Ríos M, Roé-Crespo E, et al. - In this multicenter, randomized, double-blind, placebo-controlled, phase 2a pilot clinical trial involving 69 patients [mean (SD) age 48.4 (10.6) days], researchers tested the safety and effectiveness of timolol maleate solution, 0.5%, for the early treatment of infantile hemangioma (IH) in infants younger than 60 days. The sample consisted of patients aged 10 to 60 days with focal or segmental hemangiomas (superficial, deep, mixed, or minimal/arrested growth). Study participants were randomly assigned to receive either 0.5% topical timolol maleate solution or a placebo twice daily for 24 weeks. At 24 weeks, there were no significant differences between timolol and placebo in terms of complete or nearly complete IH resolution. At week 4, there was a significant improvement in lesion color in the timolol group, and topical timolol was well tolerated. When given during the early proliferative stage, topical timolol appears to be well tolerated in the treatment of early proliferative IH, but it appears to have minimal benefit in terms of resolving lesions.